| Name | Title | Contact Details |
|---|
Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide.
Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.
GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
An #AG biotech company focused on providing natural, science-based biological solutions for high-value crops. CSE: MGRO | OTCQB: MGROF | FRA: 0C0